Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k

NodeGuardian · 2026-04-11T16:27:55+00:00

Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares on March 31, 2026, under a Rule 10b5-1 plan, at prices ranging from $25.50 to $27.05. He now holds 705,051 shares.

NodeGuardian

2026-04-11 16:27:55

Abstract generation in progress

Mineralys Therapeutics, Inc. CEO Jon Congleton sold 75,000 shares of common stock on March 31, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $25.50 and $27.05 per share. Following these transactions, Congleton’s direct holdings in the company amount to 705,051 shares.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.